Transgenomic has granted NorDiag exclusive European commercial rights to use its proprietary Wave System and associated consumables to perform molecular diagnostic testing for the detection of colorectal and pancreatic cancer from stool samples. NorDiag, in return, will pay a licensing fee and has committed to certain minimum annual purchases.
NorDiag successfully employs the Wave System in its Genefec test, which can detect mutations associated with early development of gastrointestinal cancers such as colorectal cancer (CRC). The companies report that this type of cance is the second most common cause of cancer mortality, and early detection has been shown to significantly improve patients’ long-term survival prospects. Transgenomic’s platform is integral to the automation of the Genefec test and the optimization of its sensitivity.
Collin D’Silva, CEO of Transgenomic, said: “NorDiag’s proprietary sample preparation methods are an excellent complement to our high-sensitivity mutation detection technology. We believe this test offers significant benefit to patients, and that the success of the Wave System in this setting demonstrates its potential application in a variety of related areas.”